(a) General. CMS will establish a method and process for a manufacturer of the Part D rebatable drug to:

1. (1) Access the Rebate Report as set forth in §§ 428.401 and 428.402, including any report of a reconciled rebate amount as set forth in §§ 428.401 and 428.402;
2. (2) Submit a Suggestion of Error as set forth in §§ 428.402(c) and 428.403; and
3. (3) Pay a rebate amount as set forth in § 428.405.